Format

Send to

Choose Destination
Mol Aspects Med. 2020 Jan 16:100837. doi: 10.1016/j.mam.2019.100837. [Epub ahead of print]

Circulating cell-free DNA: Translating prostate cancer genomics into clinical care.

Author information

1
Sahlgrenska Cancer Center, University of Gothenburg, Sweden; Sahlgrenska University Hospital, Department of Urology, Gothenburg, Sweden. Electronic address: delila.gasi.tandefelt@gu.se.
2
Institute of Cancer Research, Sutton, UK; Royal Marsden National Hospital Trust, Sutton, UK.

Abstract

Only in the past decade tremendous advances have been made in understanding prostate cancer genomics and consequently in applying new treatment strategies. As options regarding treatments are increasing so are the challenges in selecting the right treatment option for each patient and not the least, understanding the optimal time-point and sequence of applying available treatments. Critically, without reliable methods that enable sequential monitoring of evolving genotypes in individual patients, we will never reach effective personalised driven treatment approaches. This review focuses on the clinical implications of prostate cancer genomics and the potential of cfDNA in facilitating treatment management.

PMID:
31954523
DOI:
10.1016/j.mam.2019.100837
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center